Paul E. Monahan

Executive Director, Senior Clinical Fellow, Research and Development, Hematology
CSL Behring
King of Prussia, Philadelphia, Pennsylvania, United States

Presentation(s):

• OC 02.3 - Etranacogene dezaparvovec hemophilia B gene therapy phase 2b trial final results: stable and durable FIX level expression over 5 years

  Saturday, June 22, 2024
  13:30 – 13:45 ICT

• PB0541 - IX-TEND: A Phase IV Observational, Long-term Follow-up Study on the Safety and Efficacy of Etranacogene Dezaparvovec in Patients with Hemophilia B

  Monday, June 24, 2024
  13:45 – 14:45 ICT